Omega Therapeutics Inc
NASDAQ:OMGA
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Omega Therapeutics Inc
NASDAQ:OMGA
|
2.7m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
383.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.2B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
181.9B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.9B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.7B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.6B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Omega Therapeutics Inc
Glance View
Omega Therapeutics, Inc. engages in the development of DNA-sequence-targeting, mRNA-encoded therapeutics. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2021-07-30. The firm is engaged in a systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming platform. Its OMEGA Epigenomic Programming platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. The company has deciphered the three-dimensional architecture of the human genome and its accompanying regulators, which are organized into distinct and evolutionarily conserved structures called Insulated Genomic Domains (IGDs). The OMEGA platform enables to systematically identify and validate thousands of DNA-sequence-based epigenomic zip codes within IGDs. Its pipeline consists of early-stage, preclinical programs that span regenerative medicine, multigenic diseases including immunology, oncology, and select monogenic diseases.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Omega Therapeutics Inc is -902.9%, which is above its 3-year median of -2 832.6%.
Over the last 3 years, Omega Therapeutics Inc’s Net Margin has increased from -27 759.3% to -902.9%. During this period, it reached a low of -27 759.3% on Mar 31, 2022 and a high of -902.9% on Oct 30, 2024.
